Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1582P - Thromboembolic disease in COVID-19 cancer patients: Impact on overall survival and prognostic factors

Date

16 Sep 2021

Session

ePoster Display

Presenters

Ana Pertejo

Citation

Annals of Oncology (2021) 32 (suppl_5): S1129-S1163. 10.1016/annonc/annonc713

Authors

A. Pertejo, S. Martinez Recio, D. Jimenez-Bou, J. Peña-Lopez, I. Ruiz-Gutierrez, G. Martín-Montalvo Pérez, A. Rueda-Lara, V. Martinez Marin

Author affiliations

  • Medical Oncology, Hospital Universitario La Paz, 28046 - Madrid/ES
More

Abstract 1582P

Background

An increased risk of thromboembolic events (TE) is associated with COVID-19 infection. However, information available about thrombosis risk in COVID-19 cancer patients (Ca-P) is still scarce.

Methods

We retrospectively evaluated 219 Ca-P who were diagnosed of COVID-19 infection in our institution during the first pandemic wave. The study population was monitored for 12 months, and TE were recorded. A descriptive analysis of baseline and follow-up clinical characteristics was performed. Potential prognostic factors for developing TE and overall survival (OS) were analysed using logistic and cox proportional regression models.

Results

Overall TE rate was 13%. TE were reported during COVID-19 hospitalization (52%) and during follow-up (48%), the median time from COVID-19 diagnosis to TE was 12 weeks (w). Reported TE included pulmonary embolism (68%), deep vein thrombosis (16%), and other arterial thrombosis (16%). Pooled mortality rate among patients with TE was 52%, and 41% among patients without TE. Univariate analysis revealed haemoglobin <10g/dL, D-dimer >3000 ng/mL, PCR >5 ng/mL, LDH >190 UI/L and ferritin > 296 ng/mL during follow-up as significant prognostic factors for TE. Only ferritin > 296 ng/mL remained significant after multivariate analysis. Neither being on any specific oncological treatment nor prior anticoagulant therapy influenced TE risk. No differences in OS were found between patients who developed TE and those who did not. Though, diagnosis of TE during COVID-19 hospitalization conferred poorer survival (12 vs 52 w, p=0.02). Also, being hospitalized for COVID-19 infection was a prognostic factor for worse survival (27 vs 52 w, p=0.03). On multivariate analysis, only acute respiratory distress syndrome, metastatic disease, poor performance status, and history of TE before COVID-19 diagnosis remained significant predictors for poorer survival, and thromboprophylaxis during COVID-19 hospitalization as a predictor for better survival outcomes.

Conclusions

TE in COVID-19 Ca-P can lead to fatal outcomes. Thrombotic risk may persist after acute infection; therefore, routine active surveillance should be considered. Larger studies are needed for developing a risk prediction tool for TE in COVID-19 Ca-P.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.